On one hand, the impact of the repeat expansion on C9orf72 physiology (i.e. epigenetics, transcription, protein levels et cetera) and functionality (i.e. downstream targets) in C9 ALS/FTD patients needs to be assessed. The gene discussed is C9orf72; the disease is frontotemporal dementia.